Technical issues: flow cytometry and rare event analysis

International Journal of Laboratory Hematology - Tập 35 Số 3 - Trang 344-350 - 2013
Benjamin D. Hedley1, Michael Keeney1
1Special Hematology London Health Sciences Centre London ON Canada

Tóm tắt

SummaryFlow cytometry has become an essential tool for identification and characterization of hematological cancers and now, due to technological improvements, allows the identification and rapid enumeration of small tumor populations that may be present after induction therapy (minimal residual disease, MRD). The quantitation of MRD has been shown to correlate with relapse and survival rates in numerous diseases and in certain cases, and evidence of MRD is used to alter treatment protocols. Recent improvements in hardware allow for high data rate collection. Improved fluorochromes take advantage of violet laser excitation and maximize signal‐to‐noise ratio allowing the population of interest to be isolated in multiparameter space. This isolation, together with a low background rate, permits for detection of residual tumor populations in a background of normal cells. When counting such rare events, the distribution is governed by Poisson statistics, with precision increasing with higher numbers of cells collected. In several hematological malignancies, identification of populations at frequencies of 0.01% and lower has been attained. The choice of antibodies used in MRD detection facilitates the definition of a fingerprint to identify abnormal populations throughout treatment. Tumor populations can change phenotype, and an approach that relies on ‘different from normal’ has proven useful, particularly in the acute leukemias. Flow cytometry can and is used for detection of MRD in many hematological diseases; however, standardized approaches for specific diseases must be developed to ensure precise identification and enumeration that may alter the course of patient treatment.

Từ khóa


Tài liệu tham khảo

10.1002/cyto.990050207

10.1155/2010/426218

10.1016/j.drudis.2012.01.011

10.1111/j.1538-7836.2012.04681.x

10.1158/1078-0432.CCR-12-1585

10.1158/0008-5472.CAN-11-1254

10.1007/978-1-61737-950-5_12

10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO;2-H

10.1002/cyto.b.20071

10.1038/sj.leu.2404815

10.1182/blood-2007-06-093906

10.1182/blood-2008-01-132837

10.1182/blood-2011-08-363291

10.1200/JCO.2011.41.5323

10.6004/jnccn.2012.0105

10.1111/j.1751-553X.2012.01416.x

10.1038/leu.2012.216

10.1038/sj.leu.2404584

10.1002/cyto.b.20511

10.1056/NEJM199808273390904

10.1200/JCO.2000.18.11.2273

10.1182/blood-2004-03-1036

10.3324/haematol.11080

10.1182/blood-2012-02-408336

10.1182/blood.V98.1.29

10.1038/leu.2012.120

10.1182/blood-2012-06-435081

Wering ER, 1995, Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia, Leukemia, 9, 1523

10.1038/sj.leu.2403559

10.1002/cyto.b.20408

Borella L, 1979, Shifts in expression of cell membrane phenotypes in childhood lymphoid malignancies at relapse, Blood, 54, 64, 10.1182/blood.V54.1.64.64

10.1038/sj.leu.2401741

10.1038/sj.leu.2403303

10.1016/j.cll.2007.05.013

Thông tin
Thông tin xuất bản

International Journal of Laboratory Hematology

Tập 35 Số 3

344-350

Thông tin tác giả